Citations

Clear

4 citation(s) found for "Chan, Timothy An-thy".

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032001).
Gupta, S, Sridhar, Srikala S., Chen, Ronald C., Chan, Timothy An-thy, Wen, Yujia , Berg, S., Yen, Aihua Edward, Baghaie, Shiva, Singh, Parminder, Reimers, Melissa A., Morris, M J, Galsky, Matthew D., Rosenberg, Jonathan E., Gupta, Shilpa , Ballman, Karla V. , Apolo, Andrea B , Sridhar, Srikala S , Chan, Timothy An-thy, Singh, Parminder Pal , Reimers, Melissa A. , Morris, Michael J. , Rosenberg, Jonathan E

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4514-4514

10.1200/jco.2026.44.16_suppl.4514 Get It

4514 Background: Maintenance avelumab is a standard of care in patients (pts) with la/mUC who do not progress after first-line PBC. Cabozantinib (CABO) is an oral inhibitor of MET, VEGFR and TAM, active in multiple solid tumors. We hypothesized that an avelumab (Av)-CABO combination would improve outcomes in pts with mUC with an acceptable safety profile compared to avelumab maintenance alone. Methods: MAIN-CAV (NCT05092958) is a phase III randomized, multicenter, international trial for la/mUC pts who did not progress after 4-6 cycles of any PBC (gemcitabine-cisplatin, gemcitabine-carboplatin, MVAC, ddMVAC). Pts were randomized 1:1 to Av 800 mg IV every 2 weeks alone or with CABO 40 mg daily for ≤2 years. Stratification factors were response to first-line PBC (complete response [CR] vs partial response [PR] vs stable disease [SD]) and visceral metastases. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), safety and quality of life. The target accrual was 654 pts; the trial closed early after enrollment of 68 pts following adoption of enfortumab vedotin plus pembrolizumab as the new preferred first-line standard in the US. Results: From 3/2022 to 3/2024, 68 pts were randomized (Av n = 33; CABO-Av n = 35). Median OS was 24.8 months (mo) with Av and 23.0 mo with Avb-CABO (Hazard ratio 1.41; 95% CI 0.66–3.01; p = 0.186). Median PFS was 4.6 mo with Av vs 6.0 mo with Av-CABO (p = 0.343). Objective response rate among pts with PR or SD after first-line PBC was 20.8% with Av vs 11.5% with Av-CABO (p = 0.424). Grade ≥3 treatment-related adverse events occurred in 24.2% pts on the Av arm vs 39.4% of pts on the Av-CABO arm and CABO dose reductions occurred in 63% of pts. Conclusions: Addition of CABO to Av did not improve OS or PFS compared with Av alone in this underpowered, prematurely closed phase III trial; safety was consistent with known profiles. U10CA180821,U10CA180882; U24CA196171, U10CA180863. (CCTG);U10CA180888 (SWOG); https://acknowledgments.alliancefound.org. Clinical trial information: NCT05092958 .
Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling
Sloan, Anthony , Bukenya, George, Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair, Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Lohoff, Falk W. , Goodman, Wendy A., Miller, Tyler E., O’Connor, Christine M. , Lathia, Justin D. , Sloan, Anthony R , Luo, Jingqin , Rubin, Joshua B , Stavrou, Evi X , O'Connor, Christine M , Cameron, Scott J , Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair , Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Stavrou, Evi X. , Goodman, Wendy A., Miller, Tyler E., Nieman, Marvin T. , Sangwan, Naseer , Chan, Timothy An-thy , Khorana, Alok A. , Dhawan, Andrew , Cameron, Scott J.

Mayo Clinic

No container title available | August 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.06.668464 | PMID 41959130 Get It

Abstract Sex differences in cancer outcome, including that of glioblastoma (GBM), are shaped by biological, hormonal, and immunological factors and impact disease progression, treatment responses, survival, and tumor microenvironment (TME) interactions. Platelets regulate the immune responses and tumor progression in many cancers, but it is not clear how they contribute to these sex-based differences by affecting the dynamics of the TME. Here, we show that GBM patients exhibit heightened platelet reactivity driven by PAR4 signaling. In murine GBM models, both pharmacological inhibition of PAR4 using BMS986120 and genetic deletion of PAR4 significantly prolong survival in females but not males. This survival advantage is estrogen dependent: it is preserved in chromosomal male-hormonal female mice within the four-core genotype model and is rescued in ovariectomized mice treated with estrogen. The survival benefit is TME specific and is mediated by platelet-driven enhancement of CD8⁺ T cell infiltration into the tumor. Inhibition of platelet PAR4 signaling increases calcium signaling through an estrogen-dependent interaction between PAR4 and estrogen receptor β (ERβ)—a receptor interaction not previously described. PAR4-activated platelets within the TME suppress CD8⁺ T cell function, and depletion of CD8⁺ T cells abolishes both the tumor-induced platelet reactivity and the survival benefit conferred by PAR4 inhibition. These findings establish platelet-mediated PAR4 signaling as a critical driver of tumor progression and identify sex-specific immune responses as key to therapeutic efficacy.
Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer
Bari, Shahla , Matejcic, Marco , Xie, Hao , Teer, Jamie K. , Felder, Seth , Schmit, Stephanie L. , Kim, Richard D. , Şahin, İbrahim Halil , Powers, Benjamin D. , Chan, Timothy An-thy

Mayo Clinic

JAMA Network Open | March 20, 2025 | Volume: 8 | Issue: 3 | Pages: e251186

10.1001/jamanetworkopen.2025.1186 | PMID 40111368 Get It

ImportanceImmune checkpoint inhibitors (ICIs) have been approved for treatment of microsatellite instable (MSI-H) metastatic colorectal cancer (mCRC), but factors associated with receipt and efficacy of ICIs in routine clinical practice remain largely unknown.ObjectiveTo identify factors associated with receipt of ICIs and associated survival outcomes among patients with mCRC in routine clinical practice.Design, Setting, and ParticipantsThis population-based cohort study used deidentified data from a nationwide electronic health record–derived database to include 18 932 patients diagnosed with mCRC between January 2013 and June 2019. Population-based patients were diagnosed with de novo mCRC and had at least 2 documented clinical visits on or after the date of diagnosis. The study analyses were performed between September 2020 and April 2021.ExposurePatients received ICI therapy and/or chemotherapy as part of a systemic treatment for mCRC.Main Outcomes and MeasuresThe outcomes were receipt of ICI therapy, overall survival (OS), and time to treatment discontinuation (TTD).ResultsIn this cohort study of 18 932 patients diagnosed with mCRC (10 537 [55.7%] male; 546 [2.9%] Asian, 2005 [10.6%] Black or African American, 1674 [8.8%] Hispanic, 12 338 [65.2%] White, 4043 [21.4%] unknown race or ethnicity; median [IQR] age at metastatic diagnosis, 64.6 [55.0-73.3] years), patients with MSI-H tumors had a significantly higher probability of receiving ICIs than those with microsatellite stable (MSS) tumors (odds ratio [OR], 22.66 [95% CI, 17.30-29.73]; P < .001), whereas patients initially diagnosed with synchronous mCRC had significantly lower odds of receiving ICIs than patients with metachronous mCRC (OR, 0.57 [95% CI, 0.45-0.73]; P < .001). Patients with MSI-H tumors who received ICIs as first line of therapy had significantly longer OS than those receiving chemotherapy only (HR, 0.37 [95% CI, 0.25-0.56]; P < .001). Among patients with MSS tumors, ICI-based therapy was associated with significantly longer OS for patients with high albumin level (vs low: HR, 0.28 [95% CI, 0.18-0.45]; P < .001) and antibiotic use (vs nonuse: HR, 0.43 [95% CI, 0.27-0.67]; P < .001), but a significantly shorter OS for patients with synchronous mCRC (vs metachronous: HR, 1.90 [95% CI, 1.24-2.89]; P = .003). In addition, 29 out of 235 patients with MSS tumors (12.3%) experienced durable responses on ICI-based therapy. Similar patterns of associations with TTD were observed.Conclusions and RelevanceIn this cohort study of patients with mCRC, clinical characteristics were associated with different survival outcomes in patients treated with ICI-based therapy, with important clinical implications for patients with MSS tumors who are generally unresponsive to immunotherapy.
Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial
Sherman, Eric J. , Pei, Xin , Grkovski, Milan , Paudyal, Ramesh , Katabi, Nora , Yamaguchi, Takafumi N. , Daniel, J. , Lee, Simon , Shah, Rachna , Ratnakumar, Abhirami , Salcedo, Adriana , Tsai, C. Jillian , McBride, Sean M. , Boyle, Jay, Singh, Bhuvanesh , Damerla, Rama Rao , Paula, Arnaud Da Cruz , Price, Katharine A. , Moore, Eric J. , García, Joaquín J. , Foote, Robert L. , Humm, John L. , Shukla‐Dave, Amita , Pfister, David G. , Lee, Nancy Y. , Pei, Xin , Grkovski, Milan , Paudyal, Ramesh , Yamaguchi, Takafumi N , Ma, Daniel , Shah, Rachna , Kumar, Rahul , Kuo, Fengshen , Ratnakumar, Abhirami , Tsai, Chiaojung J , Morris, Luc G T , Higginson, Daniel S , Price, Katharine, Moore, Eric J , Foote, Robert , Boutros, Paul C , Shukla-Dave, Amita , Riaz, Nadeem , Schöder, Heiko , Selenica, Pier , Kumar, Rahul , Kuo, Fengshen , Aleynick, Nathan , Brown, David N. , Zhang, Zhigang , Hatzoglou, Vaios , Liu, Lydia , Higginson, Daniel S. , Ho, Alan L. , Wong, Richard J. , Chan, Timothy An-thy , Powell, Simon N. , Boutros, Paul C. , Reis‐Filho, Jorge S. , Tsai, CJillian

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 11, 2020 | Volume: 113 | Issue: 6 | Pages: 742-751

10.1093/jnci/djaa184 | PMID 33429428 Get It

Abstract Background Patients with human papillomavirus–related oropharyngeal cancers have excellent outcomes but experience clinically significant toxicities when treated with standard chemoradiotherapy (70 Gy). We hypothesized that functional imaging could identify patients who could be safely deescalated to 30 Gy of radiotherapy. Methods In 19 patients, pre- and intratreatment dynamic fluorine-18-labeled fluoromisonidazole positron emission tomography (PET) was used to assess tumor hypoxia. Patients without hypoxia at baseline or intratreatment received 30 Gy; patients with persistent hypoxia received 70 Gy. Neck dissection was performed at 4 months in deescalated patients to assess pathologic response. Magnetic resonance imaging (weekly), circulating plasma cell-free DNA, RNA-sequencing, and whole-genome sequencing (WGS) were performed to identify potential molecular determinants of response. Samples from an independent prospective study were obtained to reproduce molecular findings. All statistical tests were 2-sided. Results Fifteen of 19 patients had no hypoxia on baseline PET or resolution on intratreatment PET and were deescalated to 30 Gy. Of these 15 patients, 11 had a pathologic complete response. Two-year locoregional control and overall survival were 94.4% (95% confidence interval = 84.4% to 100%) and 94.7% (95% confidence interval = 85.2% to 100%), respectively. No acute grade 3 radiation–related toxicities were observed. Microenvironmental features on serial imaging correlated better with pathologic response than tumor burden metrics or circulating plasma cell-free DNA. A WGS-based DNA repair defect was associated with response (P = .02) and was reproduced in an independent cohort (P = .03). Conclusions Deescalation of radiotherapy to 30 Gy on the basis of intratreatment hypoxia imaging was feasible, safe, and associated with minimal toxicity. A DNA repair defect identified by WGS was predictive of response. Intratherapy personalization of chemoradiotherapy may facilitate marked deescalation of radiotherapy.